MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.
Leiomyosarcoma|Liposarcoma|Synovial Sarcoma|Angiosarcoma|Undifferentiated Pleomorphic Sarcoma|Epithelioid Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Fibrosarcoma|Pleomorphic Rhabdomyosarcoma|Endometrial Stromal Sarcoma|Desmoplastic Small Round Cell Tumor
BIOLOGICAL: MASCT-I|DRUG: Doxorubicin|DRUG: Ifosfamide
Progression-Free Survival (PFS), The time from the date of randomization to the first occurrence of radiological progression or death, whichever comes first., 3 years
Overall Survival (OS), The time from the date of randomization to the date of death from any cause., 3 years|Objective Response Rate (ORR), The percentage of participants with complete response (CR) or partial response (PR) via investigator assessment per RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.1 relative to the total number of participants in the analysis population., 3 years|Disease Control Rate (DCR), The percentage of participants with CR, PR, or stable disease (SD) relative to the total number of participants within the analysis population as determined by Investigators per RECIST v1.1., 3 years|Duration of response (DoR), The time from first documentation of response of PR or better to first documentation of disease progression or death from any cause, whichever comes first., 3 years|Adverse events and serious adverse events, All adverse events and serious adverse events during the study, 3 years|Adverse events and serious adverse events related to MASCT-I, All adverse events and serious adverse events related to MASCT-I during the study, 3 years|Rate and severity of clinically-significant abnormalities in laboratory testings, Clinically-significant abnormalities in laboratory testings., 3 years
Immune response to tumor-associated antigens, Measured by enzyme linked immunospot assay, 3 years
This is a multicenter, randomized, open-label study to evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with metastatic or recurrent unresectable advanced soft tissue sarcoma.